Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis

Abstract

Abstract. This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small-cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and Chinese Biomedical Literature databases were searched to identify all randomized controlled trials comparing IEP to EP in patients with histologically proven SCLC. Two investigators independently assessed the quality of the relevant trials and extracted data. We analyzed the data using Review Manager software, version 4.2.8. A total of 4 trials with 447 previously untreated SCLC patients were included in this meta-analysis. The results of the meta-analysis indicated that there were no significant differences in the overall response [relative risk (RR) = 1.07, 95% confidence interval (CI): 0.97-1.19], 1-year survival rate (RR=1.22, 95% CI: 0.96-1.55) and 2-year survival rate (RR=1.52, 95% CI: 0.75-3.07) between the IEP and EP regimens. However, there were significant differences between the IEP and EP regimens regarding the incidence of grade 3̸4 neutropenia (RR=1.52, 95% CI: 1.07-2.17) and grade 3̸4 vomiting (RR=1.78, 95% CI: 1.02-3.11). In conclusion, our results suggested that IEP is not superior to EP regimen for the treatment of previously untreated SCLC, whereas the IEP regimen is associated with more severe hematological and gastrointestinal toxicities compared to EP. Therefore, the use of ifosfamide in multimodality treatment regimens requires further investigation.

Ifosfamide-loaded lipid-core-nanocapsules to increase the anticancer efficacy in MG63 osteosarcoma cells

“…IFS is mainly metabolized through CYP 3A4 and CYP 2B6 enzymes. Ifosfamide is used in the treatment of a variety of solid tumors including those of the cervix, endometrium, lung, ovary, testes and thymus as well as in sarcoma and in the treatment of Burkitt’s lymphoma (Yang et al, 2015). IFS mainly act by crosslinking DNA strands and inhibits the replication of DNA and leads to cell apoptosis.…”

Effect of Ifosfamide on corneal genetic material and the role of lecithin and quercetin

“…Percentage tail DNA calculated by the equation Tail DNA% = 100 x Tail DNA Intensity/Cell then DNA tail moment can be measured using the following methods: Extent Tail Moment = Tail DNA% x Length of Tail. Analysis of comet images were summarized in figure (2) to reflect the comet parameters resulted from Komet program which are percentage tail cells, tail length in µm, percentage tail DNA and tail moment. The values of these parameters for control group were 4 ± 2%, 1.89 ± 1.00 µm, 1.29 ± 0.9 % and 2.44 ± 0.1 units, respectively as shown in table (1).…”